ARA-290 Dosage: How Pepti Prescribes the Peptide, in Units, mL and mg

The price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. These are the typical printed directions; your own directions are the ones on your vial. One strength is supplied.

ARA-290 is an eleven-amino-acid peptide whose sequence was taken from one helix of erythropoietin, the hormone that tells bone marrow to make red blood cells. It was engineered, not found in nature, and introduced in a 2008 paper in the Proceedings of the National Academy of Sciences. Its international non-proprietary name is cibinetide, and older papers call it helix B surface peptide. It is described as engaging a tissue-protective receptor assembly, called the innate repair receptor, without binding the receptor pair that drives red cell production, so it does not raise haemoglobin. The full reference is what is ARA-290.

Pepti's directions are written in two forms, millilitres and units, because prescriptions are written in millilitres and insulin syringes are marked in units. On a U-100 insulin syringe, 1 unit is 0.01 mL, so 100 units is 1 mL and 25 units is 0.25 mL. A unit is a volume mark on the barrel, not a measure of how strong the medication is.

The milligram figure comes from the concentration. Pepti's ARA-290 is supplied at 2 mg/mL, so:

That arithmetic is a way to read a label, not a way to set a dose. A vial labelled 10 mg is not a 10 mg dose: it is twenty 0.5 mg doses. If your label and your syringe seem to disagree, do not dose; message your care team. How long does a peptide vial last explains every number on a vial label in more detail.

The chart below is the conversion for a 2 mg/mL vial, drawn with a U-100 insulin syringe. It is math only. It is not a menu of doses, and the only line that applies to you is the one that matches the number printed on your vial.

The rule behind every row: units divided by 100 gives millilitres, and millilitres multiplied by 2 gives milligrams. A chart written for a different concentration, or for a research powder mixed at home, gives different milligrams for the same units and does not transfer to this vial. That is the main reason not to dose from a chart, including this one.

ARA-290 is supplied as a vial and syringe only. There is no pen cartridge, capsule or nasal spray, so the syringe units are always how the dose is measured.

At Pepti's typical directions, one 10 mg vial lasts four weeks:

Four weeks is why refills run every 28 days, one vial per fill. It also happens to match the treatment length the human trials studied. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Nothing is mixed at home. The peptide is broken down quickly by enzymes in blood, which is part of why it is injected rather than swallowed, but in the vial it is stable when kept cold. Keep the vial in the fridge and follow the beyond-use date printed on the label, which runs from first puncture. How to store peptides covers storage.

If a vial runs short before the refill, message your care team rather than adjusting anything yourself. If you miss a weekday dose, follow your directions and do not take two doses to make up for one.

Once daily, Monday through Friday

The weekday schedule is a prescribing pattern, not a trial design: the trials dosed daily. Five doses a week makes 20 doses land at four weeks. Pepti's directions do not name a time of day; if yours do, follow them.

Under the skin

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. The 2013 sarcoidosis trial and the 2015 diabetes trial both used daily subcutaneous self-injection, so this route is the one with human data behind it. There is no logic to injecting near a painful area: the mechanism described is systemic, through a receptor expressed where tissue is inflamed. Technique is in how to inject peptides safely.

ARA-290 has more human trial data than most compounded peptides: small, short, randomized phase 2 trials, all run by the group that designed it. The schedules are often quoted online as protocols. They were set by the developer for specific patient groups:

Three points follow. First, every subcutaneous trial dosed daily for four weeks; none used a weekday schedule or the amount in Pepti's vial. Second, the 2017 dose-ranging trial found that only the middle of three doses separated from placebo on corneal nerve fibre area, so more was not better in that study. Third, no trial dosed for longer than four weeks, apart from the twelve-week open-label study in a different condition, so there is no human data on what longer courses do. That is why your directions come from a physician who has reviewed your intake, not from a study table. What the trials found is in ARA-290 benefits.

Your physician sets your directions after reviewing your intake. Things that can lead to different directions, or a different product, include:

When directions change, the new numbers are printed on the new label. Never carry a number over from a previous fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Across the human trials, intravenous and subcutaneous, investigators reported no safety concerns from clinical or laboratory assessments, and the twelve-week study found no antibodies against the peptide. That is a clean record over short courses in small groups; long-term data does not exist. The design purpose, no effect on red cell production, held up in the trials.

ARA-290 is not used in pregnancy or breastfeeding, where safety data is absent. It is named as a prohibited peptide in the anti-doping literature, and detection methods for it have been published, so tested athletes should check the current list for their sport.

As of the FDA's 14 May 2026 update, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding: the nomination lacked enough supporting information for the FDA to evaluate it. It is not on the Category 2 list of substances with identified safety concerns, and it was not among the peptides the Pharmacy Compounding Advisory Committee reviewed in July 2026. It has never been approved by the FDA or any other regulator, and compounded medications are not FDA approved.

ARA-290 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration, so even the concentration your units chart depends on is unknown. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes ARA-290 in every state except Oklahoma, plus DC What to check on any provider is in how to tell if a peptide seller is legitimate.